EXHIBIT 1
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act
of 1934, as amended, the undersigned agree to the joint filing on behalf of
each of them of a Statement on Schedule 13D (including any and all
amendments thereto) with respect to the Common Stock of Aronex
Pharmaceuticals, Inc., a corporation incorporated in Delaware, and further
agree that this Joint Filing Agreement shall be included as an Exhibit to
such joint filings.
The undersigned further agree that each party hereto is responsible
for timely filing of such Statement on Schedule 13D and any amendments
thereto, and for the accuracy and completeness of the information
concerning such party contained therein; provided, however, that no party
is responsible for the accuracy or completeness of the information
concerning any other party, unless such party knows or has reason to
believe that such information is inaccurate.
This Joint Filing Agreement may be signed in counterparts with the
same effect as if the signature on each counterpart were upon the same
instrument.
IN WITNESS WHEREOF, the undersigned have executed this Agreement as of
January 25, 2000.
Paragon Associates and Paragon Associates II
Joint Venture
/S/ XXXXXXXX XXXX III
----------------------------------------
Xxxxxxxx Xxxx III, Authorized Agent
The Xxxxxxxx Xxxx Foundation
/S/ XXXXXXXX XXXX III
----------------------------------------
Xxxxxxxx Xxxx III, President
